Roussy, J.F., et al. Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. Clin Infect Dis, 2026 Apr 29, ciag208. PMID: 42054374
This phase III open-label study evaluates the immunogenicity and safety of co-administering two adjuvanted vaccines: the AS01E-adjuvanted RSV prefusion F protein vaccine (Arexvy) and the AS01B-adjuvanted recombinant herpes zoster subunit vaccine (Shingrix) in adults aged 50 years and older. Uniquely, the study investigates the co-administration of two vaccines containing the same AS01 adjuvant system, an area previously unexplored in clinical trials, providing important insights into potential immunological interactions and reactogenicity profiles.
The paper provides evidence that co-administration of the RSVPreF3 and RZV vaccines does not result in immunological interference or increased reactogenicity, supporting their concurrent use. Despite both vaccines containing the AS01 adjuvant system, their combined administration produced non-inferior immune responses compared to sequential dosing, suggesting minimal interaction or interference between the adjuvants in this context.
The findings demonstrate that co-administration elicits non-inferior immune responses for both vaccines while maintaining acceptable safety and reactogenicity profiles. This work is particularly important because it supports the feasibility of integrating potent adjuvanted vaccines into adult immunization schedules, potentially improving vaccination coverage and reducing healthcare visits for older populations at risk for RSV and herpes zoster, two diseases for which effective adjuvanted vaccines are essential for protection.
Click here to access the full scientific paper.
